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Abstract Binding surfaces of the type II transforming growth
factor (TGF)-L receptor extracellular domain (TLRII-ECD) are
mapped by combining scanning-deletion mutagenesis results with
knowledge-based modeling of the ectodomain structure. Of the
17 deletion mutants produced within the core binding domain of
TLRII-ECD, only three retained binding to TGF-L. Comparative
modeling based on the crystal structure of the activin type II
receptor extracellular domain (ActRII-ECD) indicates that the
TLRII mutants which retain TGF-L binding are deleted in some
of the loops connecting the L-strands in the TLRII-ECD model.
Interpretation of the mutagenesis data within the structural
framework of the ectodomain model allows for the prediction of
potential binding sites at the surface of TLRII-ECD.
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1. Introduction
Transforming growth factor-Ls (TGF-Ls) belong to a super-
family of factors that include activins, inhibins, the bone mor-
phogenetic proteins and related morphogenetic peptides.
Three closely related TGF-L isoforms (TGF-L1, -L2 and
-L3) are found in mammals and these regulate many critical
cellular processes such as cell growth, di¡erentiation, extra-
cellular matrix deposition and immune function [1,2]. The bio-
logical e¡ects of TGF-Ls are mediated by speci¢c cell surface
receptors which are present on almost all cell types [3]. Most
cells have three types of TGF-L receptors designated as type I,
type II and type III [4]. The type I [5] and type II [4] receptors
are transmembrane serine/threonine kinases which have
shown to be directly involved in signal transduction by form-
ing a signaling complex in response to ligand binding [6]. The
type I receptor is a 50^60 kDa protein that requires the pres-
ence of the type II receptor for TGF-L binding. In contrast,
the type II receptor, a 75^85 kDa protein, can bind the ligand
independently [6,7], but requires the presence of the type I
receptor for signaling [6^8]. The type III receptor, also known
as L-glycan, is a 200^300 kDa transmembrane proteoglycan
which appears to ‘present’ TGF-L to the signaling receptors
[9] by complexing with them in response to ligand. The en-
hancement of ligand binding by the type III receptor to the
signaling receptors is particularly obvious for TGF-L2 since
the signaling receptors alone have minimal a⁄nity for this
isoform. The absence of an obvious signaling motif in the
cytoplasmic domain of the type III receptor, together with
the fact that various TGF-L responsive cells lack the type
III receptor [10,11], suggests that this receptor does not par-
ticipate directly in TGF-L signal transduction. According to
this model of TGF-L receptor signaling complex formation,
the type II receptor can be considered as the primary sensor
for the presence of TGF-L, the type I receptor as the e¡ector
and the type III receptor as an enhancer of the e¡ective con-
centration of TGF-L. Although this overall scheme for the
interaction of TGF-L with its receptors has been mapped
out, very little is known about the structure of TGF-L recep-
tor ectodomains. Only a few mutagenesis studies have been
done to determine which subdomains and residues within the
ectodomains are critical for ligand-receptor and receptor-re-
ceptor interactions.
With respect to the type III receptor, the original studies on
mapping of the ligand binding site(s) within the ectodomain
reported contradictory results. Two of the studies reported
that a single binding site was located in the membrane prox-
imal region of the ectodomain [12,13], while a third study
localized a single binding site to the amino-terminal region
[14]. More recent studies have suggested that the type III
receptor contains two independent ligand binding sites
[15,16]. However, it is not clear which of these is the predom-
inant binding site [17,18]. No structural information is avail-
able on either of these ligand binding subdomains and de-
tailed mutagenesis studies on the subdomains have not been
reported.
In the case of the type I receptor, a three-dimensional (3D)
model of the ectodomain has been constructed based on com-
mon sequence and structural features between the type I re-
ceptor and CD59 (protectin) [19]. The modeled structure con-
tained four extending ¢ngers and two clusters of charged
residues. No mutagenesis studies have been reported on this
ectodomain. Accordingly, it is not known which residues and
structural determinants are important for the function.
With respect to the type II TGF-L receptor, one study,
published by our group, reported a partial mapping of the
extracellular ligand binding domain based on a scanning-dele-
tion mutagenesis strategy [20]. In this analysis, a core binding
domain for TGF-L was found to lie between amino acids 51
and 152 of the human type II TGF-L receptor extracellular
domain (TLRII-ECD). However, no structural information is
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presently available for the ectodomain of this receptor. More
recently, the crystal structure of the extracellular domain of
type II activin receptor (ActRII-ECD) has been experimen-
tally resolved by X-ray crystallography [21]. It indicates that
ActRII-ECD, and most likely the other family members in-
cluding TLRII-ECD, adopt a fold similar to that of a class of
toxins known as ‘three-¢nger toxins’. In this paper, we extend
this scanning-deletion mutagenesis to within the previously
de¢ned core binding domain of TLRII-ECD. We present a
comparative structural model for TLRII-ECD based on the
ActRII-ECD structure. The 3D model is used to rationalize
the scanning-deletion mutagenesis results at the molecular lev-
el. Structural characteristics at the surface of the TLRII-ECD
molecule which may play a role in ligand binding and specif-
icity will also be discussed.
2. Materials and methods
2.1. Mutagenesis
Mutagenesis of the human TLRII subcloned in pCDNA-3 (Invitro-
gen) was done by the USE method as previously described [20,22].
Additional primers used in this analysis are as follows (numbers cor-
respond to the deleted amino acids): v58-60: 5P-TTCTGGTTGTCA-
CATCTCACATCACAAA, v63-65: 5P-TTGCTCATGCAGGAGTC-
ACAGGTGGAAA, v68-70: 5P-GAGGTGATGCTGCAGCAGGA-
TTTCTGGT, v73-75: 5P-GGCTTCTCACAGATGCTGCAGTTGC-
TCA, v78-80: 5P-ACACAGACTTCCTGACAGATGGAGGTGA,
v83-85: 5P-TTTCTCCATACAGCTTCCTGTGGCTTCT, v88-90:
5P-ATGTTCTCGTCATTTACAGCCACACAGA, v93-95: 5P-ACT-
GTCTCTAGTGTGTCATTCTTTCTCC, v98-100: 5P-TTGGGGTC-
ATGGCATAGTGTTATGTTCT, v103-105: 5P-TCATGGTAGGG-
GAGATGGCAAACTGTCT, v108-110: 5P-TCTTCCAGAATAAA-
GGGGAGCTTGGGGT, v113-115: 5P-TTTGGAGAAGCAGCAA-
TAAAGTCATGGT, v118-120: 5P-TCCTTCATAATGCAAGCAG-
CATCTTCCA, v123-125: 5P-CCAGGCTTTTTTTTAATGCACTT-
TGGAG, v128-130: 5P-ATGAAGAAAGTCTCTTTTTTTTCCTT-
CA, v133-135: 5P-GAGCTACAGGAACAAGTCTCACCAGGCT,
v143-145: 5P-GAGAAGATGATGTTCTCATCAGAGCTAC. The
sequences of all mutants were con¢rmed by dideoxy sequencing (Phar-
macia Biotech).
2.2. Cell culture, transfection and a⁄nity labelling
293 cells were maintained in Dulbecco’s modi¢ed Eagle medium
supplemented with 10% fetal bovine serum (Hyclone). The day before
transfection, the cells were seeded at 8U104 cells/well in a 12 well dish.
The cells were transfected with 5 Wl of Superfect reagent (Qiagen) and
1.5 Wg of DNA according to the manufacturer’s protocol. To monitor
DNA uptake, 150 ng of GFPq plasmid (Quantum biotechnology) was
included in each transfection. Following 3 h of incubation with Super-
fect reagent, the cells from each transfection were washed with phos-
phate-bu¡ered saline, trypsinized and seeded in two equal aliquots.
After 48 h at 37‡C in 5% CO2, half of the cells were a⁄nity-labelled
with [125I]TGF-L1 as previously described [23]. The a⁄nity-labelled
receptors were solubilized and resolved on a reducing 4^12% gradient
SDS-PAGE and exposed on a phosphorimager screen. The resulting
image was displayed with Imagequant NT software (Molecular Dy-
namics). The remaining aliquot was use to measure GFPq DNA up-
take by Flowcytometry on an EPICS XL-MCS (Beckman/Coulter).
2.3. Molecular modeling
The 3D model of residues 47^154 of TLRII-ECD was constructed
by homology modeling using the program COMPOSER [24] imple-
mented in SYBYL 6.4 software (Tripos, St. Louis, MO, USA). The
X-ray-determined structure of ActRII-ECD, which adopts the three-
¢nger toxin fold [21] (PDB code 1bte), was used as template. The
target/template sequence alignment was adjusted manually to match
the conserved disul¢de pattern (Fig. 1b) as previously suggested [21].
Six structurally conserved regions (SCRs) were assigned in the initial
Fig. 1. (a) Schematic representation of the TLRII-ECD deletion mutants. Deleted amino acids are indicated in bold with the numbering such
that amino acid number one is the ¢rst methionine. Mutants which bind [125I]TGF-L1 are underlined. Brackets indicate the limits of the previ-
ously described core binding domain [20]. Mutants from that initial study are indicated by an asterisk. (b) Sequence alignment of the TLRII-
ECD and ActRII-ECD used in homology modeling. SCRs are enclosed in boxes. Modeled SVRs are numbered I^V. Cysteine residues are
bolded and numbered in their order of occurrence in the two sequences. Secondary structural elements as observed in the X-ray-determined
structure of ActRII-ECD and in the modeled structure of TLRII-ECD are also shown and numbered in the order in which they appear in the
sequence.
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model building. Five intervening structurally variable regions (SVRs
I^V, i.e. loops with di¡erent length in TLRII-ECD and ActRII-ECD)
were needed to complete a preliminary model structure (Fig. 1b). The
conformations of SVRs II and III were copied from the corresponding
loops with an identical length as cardiotoxin from Naja nigricollis
(PDB code 1tgx) which adopts the same three-¢nger toxin fold
[21,25]. The remaining SVRs were constructed by searching a data-
base of protein structures deposited in PDB. In selecting loop con-
formations, the search output was examined for root mean square
deviation in anchor positions, sequence homology as well as suitabil-
ity to the overall tertiary structure. Model SVR I was obtained from
hevamine A (PDB code 2hvm) and allowed proper formation of a
disul¢de bond. SVRs IV and V were modeled based on regions of
lectin (PDB code 9wga) and core Gp32 DNA binding protein (PDB
code 1gpc), respectively.
The disul¢de pattern was assembled as C1-C7, C2-C5, C3-C4, C6-
C8, C9-C10 and C11-C12 where the numbering of cysteine residues
refers to their order of occurrence in the primary sequence of TLRII-
ECD (Fig. 1b). Four of these disul¢de bonds, C1-C7, C6-C8, C9-C10
and C11-12, correspond to C1-C3, C2-C4, C6-C7 and C9-C10 disul-
¢des, respectively, found in the ActRII-ECD template structure [21].
In the initial model building of the SCRs, Cys-54 and Cys-71 were
positioned proximally enough to allow pairing (C2-C5 disul¢de) of
two out of the four additional cysteines in the N-terminal segment of
TLRII-ECD. The remaining disul¢de C3-C4 was provided by data-
base search in SVR I. N- and C-termini were blocked with acetyl- and
methylamino groups, respectively, and hydrogen atoms were added
explicitly using the BIOPOLYMER module of SYBYL 6.4. Structural
re¢nement was performed in SYBYL 6.4 by energy minimization us-
ing AMBER 4.1 all-atom force-¢eld [26] with the Powel minimizer, a
distance-dependent (4r) dielectric constant and an 8 Aî non-bonded
cut-o¡. Preliminary stages of energy minimization were performed (i)
in the SVRs only, followed by (ii) ¢xing the position of SCRs back-
bone atoms only. All the constraints were then released and the en-
ergy minimization was carried out until the root mean square of the
gradients was smaller than 0.01 kcal/mol Aî .
3. Results and discussion
In our previous scanning-deletion mutagenesis study, three
amino acid deletions were introduced at intervals of ¢ve ami-
no acids within the N-terminal and C-terminal ends of the
extracellular domain of TLRII. The resulting constructs
were analyzed by a⁄nity labelling of transfected Cos-1 cells
[20]. A core domain for TGF-L binding was mapped from
residues 51 to 152. We have now extended this analysis to
within the core domain itself by producing 17 additional de-
letion mutants (Fig. 1a). Each mutant construct was evaluated
for ligand binding by transient transfection in 293 cells. Fol-
lowing a 48 h period of expression, the cells were cross-link-
labelled with iodinated TGF-L1 and cell extracts were ana-
lyzed by SDS-PAGE and phosphorimaging. Among the 17
new mutants, only three (v108-110, v113-115 and v128-130)
were found to be a⁄nity-labelled with [125I]TGF-L at a detect-
able level. The amount of a⁄nity labelling for mutants v108-
110 and v113-115 is lower than that of mutant v128-130,
which is not signi¢cantly di¡erent from that of the wild-type
TLRII (Fig. 2).
The scanning-deletion mutagenesis results were translated
into the 3D structural context provided by a homology model
of the TLRII-ECD which is based on the recently determined
structure of ActRII-ECD [21]. The overall structure of the
TLRII-ECD model adopts the three-¢nger toxin fold compris-
ing seven L-strands which form three anti-parallel sheets (Fig.
3a). It also contains six disul¢de bonds (see Section 2), four of
which are formed by eight cysteines which are characteristic of
the three-¢nger toxin fold and conserved in ActRII-ECD [21].
The fold is further stabilized by two signi¢cant hydrophobic
clusters, one partly buried between strands L3, L6 and L7 and
the other one largely exposed at the bottom of the cavity
formed on the concave side of the extracellular domain. Sub-
stantial insertions relative to the ActRII-ECD (totaling 16
residues) occurred in the L1-L2 (¢nger 1), L4-L5 and L5-L6
(¢nger 3) loop regions (Fig. 1b) and result in a more pro-
nounced curvature of the convex and concave faces of the
TLRII-ECD molecule (Fig. 3b and c) as compared to the
ActRII-ECD template [21].
Model building of the TLRII-ECD structure allows us to
rationalize the experimental results by projecting the three
residue deletions onto the secondary structural elements and
molecular surface of the ectodomain (Fig. 3). The present
scanning-deletion analysis indicates that three TLRII-ECD
deletion mutants (v108-110, v113-115 and v128-130) are
able to bind TGF-L. This demonstrates not only that all these
mutants are both properly folded and readily expressed at the
cell surface, but more importantly that they preserve all struc-
tural determinants required for interaction with the ligand.
According to our model, these three deletions are located in
Fig. 2. A⁄nity labelling of 293 cells transiently transfected with TLRII deletion mutants. M: molecular weight markers (kDa), Wt: wild-type
TLRII, MT: empty vector. Note: for some mutants (Wt, from v103-105 to v118-120), a band corresponding to the molecular weight of the
type I TGF-L receptor is visible. This di¡erence was not seen repeatedly and results from di¡erences in the amount of endogenous type I recep-
tor that is observed in di¡erent transfections.
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rather peripheral regions within loops connecting the L-
strands (Fig. 3a). In general, deletions in such regions are
likely to induce more localized e¡ects, rather than profound
structural alterations of the domain. Two of the mutants that
bind TGF-L (v108-110 and v113-115) are deleted in the loop
connecting L4- and L5-strands (Fig. 3a). It is in this loop that
an insertion in TLRII-ECD versus ActRII-ECD occurs (Fig.
1b). The third binding mutant (v128-130) lacks three residues
in the ¢nger 3 loop of TLRII-ECD (Fig. 3a). Once again, this
is a loop where there is an insertion relative to the template
ActRII-ECD structure (Fig. 1b). We also show in our model
the deletion mutants v48-50 and v153-155 (Fig. 1a) which, we
previously demonstrated, did not alter binding [20]. Spatial
distribution of these ¢ve deletions allows for the identi¢cation
of two areas on the TLRII-ECD that are not important for
ligand binding (Fig. 3). They are located in the vicinity of (i)
residues 48^50, 108^110 and 113^115 close to the N-terminus
and (ii) residues 128^130 and 153^155 close to the C-terminus
of the domain.
Since the scanning-deletion technique is more structurally
disruptive than scanning-point mutagenesis, the functional in-
terpretation of the three residue deletions which lead to inac-
tive TLRII mutants is complicated by the fact that a lack of
binding may be due to major conformational changes in the
domain as a whole (i.e. unfolding or misfolding), at least for
some of the mutants. The homology model o¡ers an approach
to rationally interpret these non-binding mutants. Eight of the
mutants have deletions which fall, partially or completely,
within the L-sheet system (and implicitly within the hydro-
phobic clusters) which occupies a central position within the
domain structure (Fig. 3a): v53-55, v73-75, v83-85, v88-90,
v98-100, v123-125, v133-135 and v148-150. In addition, the
v143-145 deletion removes residues Cys-143 and Asn-144
(conserved in all type II receptors) thus precluding C11-C12
disul¢de bond formation and H-bond anchoring of L1- and
L3-strands, respectively. It is therefore not surprising that all
the mutants containing these deletions do not bind TGF-L, an
e¡ect that is suspected to arise from signi¢cant structural
changes in the receptor. However, the observed lack of bind-
ing might be attributed in part, at least for some of these
mutants, to the removal of important interactive binding sites
as suggested by an analysis of the surface properties of the
modeled domain molecule (see below).
The remaining seven mutants that do not bind TGF-L have
deletions in the loops connecting the L-strands of the domain
(Fig. 3a). The three deletions engineered in the ¢nger 1 loop
region (v58-60, v63-65 and v68-70) are unlikely to induce
major conformational rearrangements within the ectodomain,
since both ActRII-ECD and cardiotoxin display a much
shorter ¢nger 1 without a¡ecting the H-bond interactions be-
tween L1- and L2-strands [21,25]. Instead, it is likely that these
deletions cause only local perturbations, supporting the con-
cept that the highly variable ¢nger 1 may be important for
speci¢c binding interactions [21]. The presence of two disul¢de
bonds in ¢nger 1 (C2-C5 which sets the loop anchor positions
and C3-C4 which provides additional constraint within the
loop itself) may be required for stabilizing the bioactive con-
formation of this loop. Some of the deletions in the ¢nger 1
region may eliminate residues that are required for direct con-
tact with the TGF-L, whereas other deletions in this loop may
abolish binding indirectly by rendering the local loop confor-
mation inactive. Residues 78^80 in the loop connecting the
L2- and L3-strands may also play a role in ligand binding.
Although three residues longer, the corresponding loop in
ActRII-ECD is distorted in one of the two molecules in the
asymmetric unit and therefore, it has been speculated that this
loop may play a role in receptor recognition [21]. The elimi-
nation of residues 93^95 in the loop connecting the L3- and
L4-strands (¢nger 2) also resulted in an inactive variant of the
receptor. However, the somewhat extended conformation of
Fig. 3. Mapping of the scanning-deletion mutagenesis results onto the homology model of TLRII-ECD. (a) Ribbon representation of the
TLRII-ECD model structure. Three residue deletions are colored in red for the mutants that do not bind TGF-L and in blue for those that
bind TGF-L. Side-chains of cysteine residues are colored in yellow and shown as ball and stick with the sulfur atom represented as CPK.
Strands are numbered in the order in which they occur in the sequence. The modeled SVRs numbered I^V in Fig. 1b are also labelled. (b) Mo-
lecular surface representation of the TLRII-ECD model structure displayed with the convex side in front in an orientation similar to that
shown in a and (c) with the concave side in front corresponding to a V180‡ rotation relative to the orientation in a and b. Surface areas cor-
responding to the ¢ve deletions that lead to active mutants are colored in blue and identi¢ed as 1 for v48-50, 2 for v108-110, 3 for v113-115,
4 for v128-130 and 5 for v153-154. The molecular surface associated with the side-chain atoms of hydrophobic residues Ala, Ile, Leu, Met,
Phe, Pro and Val is colored in green and labelled by a residue number (there is only one Trp residue which is completely buried and only one
Tyr which belongs to surface area 3). Residue Glu-98 is labelled in red. Putative glycosylation sites (Asn-70, Asn-94 and Asn-154) are marked
with red arrows.
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this loop suggests that the lack of binding properties may be
due to global structural changes in the ectodomain rather
than removal of an important interacting site. The inactivity
of two of the mutants with deletions in the loop linking L4-
and L5-strands (v103-105 and v118-120) is likely to be more
directly related to the removal of speci¢c interacting residues
of the ectodomain rather than to global or local loop confor-
mational rearrangement. We conclude this since the adjacent
deletions (v108-110, v113-115) in the loop did not abolish
binding, even though the conformation of the loop would
be a¡ected.
The results of the scanning-deletion mutagenesis combined
with the knowledge-based modeling have enabled us to delin-
eate potential sites on the surface of the TLRII-ECD that are
required for the binding of TGF-L. In general, exposed hydro-
phobic patches on a protein surface tend to be part of a bind-
ing interface [27,28]. In order to assess and prioritize the po-
tential binding sites further, we mapped the position of
solvent-exposed clustered hydrophobic side-chains on the sur-
face of TLRII-ECD. It can be seen that none of the mutants
that retain activity has deletions which interfere with surface
hydrophobic regions (Fig. 3b and c). By far, the most signi¢-
cant potential protein binding interface is formed by the sol-
vent-exposed hydrophobic patch lining the bottom of the cav-
ity on the concave face of the molecule (Fig. 3c). The residues
contributing to the patch arise from the central L-strands of
the domain: Phe-53 from L1, Val-85 and Val-87 from L3,
Leu-97 and Val-100 from L4, Met-123 from L5, Phe-133
and Met-135 from L6. Some of these residues were eliminated
during the scanning-deletion analysis in mutants which do not
bind TGF-L (v53-55, v83-85, v98-100, v123-125, v133-135),
further supporting the presence of a binding interface in this
region. However, as we discussed earlier, it is di⁄cult to at-
tribute the inactivity of these mutants to only one of the two
‘concomitant’ changes that likely occur upon deletion: the
alteration of the binding site integrity and the modi¢cation
of folding properties of the ectodomain. A similar hydropho-
bic patch has been identi¢ed in the ActRII-ECD structure
[21]. Multiple conservative mutations in the corresponding
hydrophobic side-chains, complemented by di¡erences in
more localized features (e.g. the position of a small pocket
and an adjacent charge reversal, Glu-98 in TLRII-ECD versus
Lys-56 in ActRII-ECD, in the center of the patch), may play
an important role in determining the speci¢city of these type
II receptors for their natural ligands. The second signi¢cant
hydrophobic patch is located on the convex face of the mol-
ecule (Fig. 3b). There exists a corresponding patch in ActRII-
ECD as well [21]. The contributing residues belong to strands
L5 (Ile-122), L7 (Ile-147 and Ile-148) and the C-terminal part
of the loop connecting L4 and L5 (Ala-117 and Pro-119). The
importance of this patch is supported by the lack of TGF-L
binding to the deletion mutants v118-120 and v148-150 in
which residues Pro-119 and Ile-148, respectively, are not
present. It is worth stressing that all the residues forming these
two potential binding sites belong to SCRs, which are char-
acterized by higher model accuracy in comparison with mod-
eled SVRs. In addition to these two major patches, there are
two much less extended hydrophobic surface areas that may
be required for interactions. One of them, which £anks one
side of the concave face of the domain, is formed by residues
from the loop connecting L2- and L3-strands (Pro-80 was
removed in the inactive mutant v78-80) and the N-terminal
segment of the loop between L4 and L5 (Leu-106 and Pro-
107). The other one is located at the interface between ¢ngers
1 and 2 and formed by side-chains of Phe-58 and Ile-95 (res-
idues deleted in the inactive mutants v58-60 and v93-95, re-
spectively) as well as the Cys-54-Cys-71 disul¢de (disrupted in
the inactive mutant v53-55).
The interpretation above can be complemented by the re-
ported data on the e¡ect of N-glycosylation on the binding
properties of TLRII. It has been shown that the glycosylation
of either TLRII or ActRII does not signi¢cantly a¡ect ligand
binding [29,30] and therefore, these glycosylation sites should
not fall within the binding interface(s). There are three possi-
ble N-glycosylation sites within the TLRII-ECD (Asn-70,
Asn-94 and Asn-154). For ActRII-ECD, the glycosylation
of Asn-24, which corresponds to Asn-70 in TLRII-ECD, has
been demonstrated by X-ray crystallography [21]. The struc-
tural model of the TLRII-ECD shows that these three glyco-
sylation sites are accessible to the solvent (Fig. 3b). During the
scanning-deletion mutagenesis study, all the putative glycosyl-
ation sites have been removed (Asn-70 in the v68-70 mutant,
Asn-94 in the v93-95 mutant and Asn-154 in the v153-155
mutant). The fact that the deletion of the Asn-70 glycosyla-
tion site in v68-70 causes a loss of binding supports the con-
cept that residues 68^70 are important in stabilizing a partic-
ular bioactive conformation of the ¢nger 1 loop rather than
directly interacting with TGF-L. The predicted binding region
of ¢nger 1 is therefore likely positioned on the side of the loop
which is opposite to residues 68^70 facing the concave face of
the domain and corresponding to the residues deleted in the
inactive mutants v58-60 and v63-65. The inactivity of the
mutant with the putative glycosylation site Asn-94 excised
(v93-95) suggests a structural rather than interacting role
for residues 93^95, as discussed earlier. Finally, the elimina-
tion of the third possible glycosylation site, Asn-154 in v153-
155, does not alter the binding capability of this mutant. This
further supports the location of this stretch of residues as
being further away from the binding sites of the domain.
The combination of scanning-deletion mutagenesis with
structural model building is a powerful technique that has
allowed us to rationally identify putative binding sites on
the TLRII-ECD. Our results represent the ¢rst attempt to
map a functional pro¢le onto the structural features of the
TLRII-ECD. There are, however, inherent limitations in our
knowledge-based model of the domain, in particular in the
loop regions. A more precise structure of the domain has to
be determined via experimental studies (e.g. X-ray or NMR).
Further biochemical and docking experiments are currently
underway in order to more accurately map the binding inter-
face of the of type II TGF-L receptor extracellular domain
with its natural partner molecules.
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